Drugs / Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02358187 | Jan 2015 → Jan 2027 expected | low grade glioma | James Felker | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02358187 ↗ |
| Modality | Vaccine | “glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine” NCT02358187 ↗ |
| Route | Subcutaneous | “Patients will be treated with subcutaneous injections of GAA/TT-vaccines starting on Week 0 and every 3 weeks thereafter for up to 8 cycles or until Off-treatment criteria are...” NCT02358187 ↗ |